Netto, George J; Amin, Mahul B; Compérat, Eva M; Gill, Anthony J; Hartmann, Arndt; Moch, Holger; Menon, Santosh; Raspollini, Maria R; Rubin, Mark A; Srigley, John R; Hoon Tan, Puay; Tickoo, Satish K; Tsuzuki, Toyonori; Turajlic, Samra; Cree, Ian; Berney, Daniel M (2023). Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. European urology, 83(4), pp. 301-303. Elsevier 10.1016/j.eururo.2022.09.015
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0302283822026446-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (664kB) |
We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) |
UniBE Contributor: |
Rubin, Mark Andrew |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0302-2838 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
10 Oct 2022 08:01 |
Last Modified: |
25 Mar 2024 10:10 |
Publisher DOI: |
10.1016/j.eururo.2022.09.015 |
PubMed ID: |
36202687 |
BORIS DOI: |
10.48350/173604 |
URI: |
https://boris.unibe.ch/id/eprint/173604 |
Actions (login required)
 |
Edit item |